Results 241 to 250 of about 460,157 (392)

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

Vamorolone Versus Traditional Glucocorticoids in Duchenne Muscular Dystrophy: A Review and Meta-Analysis of Efficacy and Safety. [PDF]

J Pharm Technol
Javed D, Javed A, Jajja FA, Jahanzeb A.
europepmc   +1 more source

Glucocorticoids and fetal lung development

, 1977
Jane D. Funkhouser, Edwin R. Hughes
openalex   +1 more source

Antenatal glucocorticoid treatment:are we doing harm to term babies? [PDF]

, 2012
Reynolds, Rebecca M, Seckl, Jonathan R
core   +1 more source

Combined Immediate‐Release and Extended‐Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja, Susanna Kääriäinen, Zsófia Lovró, Mia Lundblad, Kristina Drott, Elsa Lilienberg, Marica T. Engström, Karla Saukkonen, Mika Scheinin   +8 more
wiley   +1 more source

Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial. [PDF]

RMD Open
Lend K, Twisk JW, Kumar N, Dijkshoorn B, Lampa J, Rudin A, Hetland ML, Uhlig T, Nordström D, Østergaard M, Gudbjornsson B, Sokka-Isler T, Grondal G, Hørslev-Petersen K, Nurmohamed MT, Frostegård J, van Vollenhoven RF.   +16 more
europepmc   +1 more source

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano, Milko Massimiliano Radicioni, Gerhard Garhöfer, Martina Cartwright, Markus Müller, Iris Kopeloff, Luigi Moro, Nicholas Squittieri, Alessandro Mazzetti   +8 more
wiley   +1 more source

Advances in the study and treatment of glucocorticoid osteoporosis: A review. [PDF]

Medicine (Baltimore)
Song X, Zhang Y, Yang H, Xiong F, Chen F.   +4 more
europepmc   +1 more source

The Relationship between Glucocorticoid Binding and Tyrosine Aminotransferase Induction in Hepatoma Tissue Culture Cells [PDF]

, 1970
John D. Baxter, Gordon M. Tomkins
openalex   +1 more source

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

Annals of the Rheumatic Diseases, 2016
C. Strehl, J. Bijlsma, M. D. de Wit, M. Boers, N. Caeyers, M. Cutolo, B. Dasgupta, W. Dixon, R. Geenen, T. Huizinga, A. Kent, A. de Thurah, J. Listing, X. Mariette, D. Ray, H. Scherer, R. Seror, C. Spies, S. Tarp, D. Wiek, K. Winthrop, F. Buttgereit   +21 more
semanticscholar   +1 more source